FORMA Therapeutics and the Experimental Therapeutics Centre of Singapore (ETC) announced today a collaboration agreement to leverage FORMA’s transformative chemistry platform to discover novel compounds for further development by ETC.  ETC is funded by the Agency for Science, Technology & Research (A*STAR) of Singapore, which is committed to fostering world-class scientific research and talent for a vibrant, knowledge-based Singapore.

“Working collaboratively with ETC will allow us to demonstrate the power of FORMA’s transformative chemistry platform across a broad range of targets pursued by ETC,” said Steven Tregay, CEO of FORMA. “We share a commitment to advancing early-stage science and translating those discoveries into practical clinical applications. This collaboration is therefore mutually beneficial, potentially bolstering Singapore’s biomedical pipeline of the future, while also further validating the productivity and efficiency of FORMA’s proprietary drug discovery technologies in identifying new, promising compounds.”

FORMA, a Bio*One portfolio company, seeks to integrate important new advances in biology and chemistry to unlock essential oncology targets that have been elusive to the best scientists in the industry. It currently has three global sites including a 12-man team in Singapore, and has drug discovery partnerships with major pharmaceutical and biotechnology players such as Novartis and Cubist Pharmaceuticals.